A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Tumor Microenvironment-Based Risk Stratification of Oropharyngeal Squamous Cell Carcinoma
Tekijät: Almangush, Alhadi; Jouhi, Lauri; Haglund, Caj; Hagström, Jaana; Mäkitie, Antti A.; Leivo, Ilmo
Kustantaja: Wiley
Julkaisuvuosi: 2025
Journal: Head and Neck
Tietokannassa oleva lehden nimi: Head & neck
Lehden akronyymi: Head Neck
Vuosikerta: 47
Numero: 2
Aloitussivu: 599
Lopetussivu: 605
ISSN: 1043-3074
eISSN: 1097-0347
DOI: https://doi.org/10.1002/hed.27945
Verkko-osoite: https://doi.org/10.1002/hed.27945
Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/458302398
BACKGROUND: Evaluation of the prognostic impact of tumor microenvironment (TME) has received attention in recent years. We introduce a TME-based risk stratification for oropharyngeal squamous cell carcinoma (OPSCC).
MATERIAL AND METHODS: A total of 182 patients treated for OPSCC at the Helsinki University Hospital were included. TME-based risk stratification was designed combining tumor-stroma ratio and stromal tumor-infiltrating lymphocytes assessed in hematoxylin and eosin-stained sections.
RESULTS: In multivariable analysis, TME-based risk stratification associated with poor disease-free survival with a hazard ratio (HR) of 2.68 (95% CI 1.11-6.48, p = 0.029). In addition, the proposed risk stratification was associated with poor disease-specific survival (HR 2.687, 95% CI 1.28-5.66, p = 0.009) and poor overall survival (HR 2.21, 95% CI 1.23-3.99, p = 0.008).
CONCLUSION: Our TME-based risk stratification provides a powerful prognostic tool that can be used in daily treatment planning of OPSCC together with tumor-related prognostic markers.
Ladattava julkaisu This is an electronic reprint of the original article. |  |
Julkaisussa olevat rahoitustiedot:
This work was supported by Finnish Cancer Society, Turku University Hospital Fund, Finska Läkaresällskapet, Maritza and Reino Salonen Foundation, K. Albin Johansson Foundation, the Finnish Dental Society Apollonia, Helsinki University Hospital Research Fund, and Sigrid Jusélius Foundation.
